Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival in mCRPC pts progressing after docetaxel. Few data are available concerning the clinical outcome of AA treatment in mCRPC in terms of the duration of prior androgen deprivation therapy (ADT). In this retrospective analysis we assessed the PFS and OS in patients affected with mCRPC according to the duration of ADT
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy / Maria Agnese Fabbri, ; Marchetti, Paolo; Cortesi, Enrico; Santini, Daniele; Teresa, Gamucci; Francesco, Angelini; Isabella, Sperduti; Flavia, Longo; Arianna, Pellegrino; Milano, Annalisa; Silvia, Quadrini; Mancini, Ml; Francesca, Primi; Fabrizio, Nelli; Raffaele, Ratta; Enzo, Ruggeri. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 34:Suppl.2(2016). (Intervento presentato al convegno 2016 ASCO Genitourinary Cancers Symposium tenutosi a San Francisco nel January 7-9) [10.1200/jco.2016.34.2].
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy
MARCHETTI, PAOLO;Enrico Cortesi;Daniele Santini;MILANO, ANNALISA;
2016
Abstract
Background: Abiraterone acetate (AA) is a potent, selective androgen (CYP17) biosynthesis inhibitor, which showed to improve overall survival in mCRPC pts progressing after docetaxel. Few data are available concerning the clinical outcome of AA treatment in mCRPC in terms of the duration of prior androgen deprivation therapy (ADT). In this retrospective analysis we assessed the PFS and OS in patients affected with mCRPC according to the duration of ADT| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabbri_Abiraterone_2016.pdf
accesso aperto
Tipologia:
Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
847.82 kB
Formato
Adobe PDF
|
847.82 kB | Adobe PDF | |
|
Fabbri_copertina_Abiraterone_2016.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
190.18 kB
Formato
Adobe PDF
|
190.18 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
